{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=55",
    "query": {
      "intervention": "Placebo- C",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 1836,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T06:28:47.785Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05592951",
      "title": "Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Safety",
        "Tolerance"
      ],
      "interventions": [
        {
          "name": "Crystal Light (once serving)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Liquid IV with amino acids (one serving)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Liquid IV with amino acids (two servings)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Liquid IV with amino acids (three servings)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Memphis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-09-30",
      "completion_date": "2023-07-18",
      "has_results": false,
      "last_update_posted_date": "2023-09-26",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05592951"
    },
    {
      "nct_id": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Clostridium butyricum CBM 588 Probiotic Strain",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab and Recombinant Human Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 718,
      "start_date": "2026-06-05",
      "completion_date": "2034-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 41,
      "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07383441"
    },
    {
      "nct_id": "NCT03220724",
      "title": "Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CH505TF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505w53",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505w78",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505 M5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 117,
      "start_date": "2017-08-22",
      "completion_date": "2023-03-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220724"
    },
    {
      "nct_id": "NCT04096560",
      "title": "A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Narcolepsy Type 1 (NT1)",
        "Narcolepsy Type 2 (NT2)"
      ],
      "interventions": [
        {
          "name": "TAK-994",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 97,
      "start_date": "2020-05-27",
      "completion_date": "2021-11-05",
      "has_results": true,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 36,
      "location_summary": "Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04096560"
    },
    {
      "nct_id": "NCT05940883",
      "title": "A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Y-2 Sublingual Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Simcere Pharmaceutical Co., Ltd",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2023-09-06",
      "completion_date": "2023-12-05",
      "has_results": false,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05940883"
    },
    {
      "nct_id": "NCT02189122",
      "title": "Comparative Effects of Aspirin and NHP-544C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Bradykinin",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 81 mg",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 162 mg",
          "type": "DRUG"
        },
        {
          "name": "NHP544-C 81 mg",
          "type": "DRUG"
        },
        {
          "name": "NHP544C 162 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 61,
      "start_date": "2014-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-07-12",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189122"
    },
    {
      "nct_id": "NCT04530539",
      "title": "The Effect of Melatonin and Vitamin C on COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Covid19",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Vitamin C",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "melatonin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Symptom Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Lancaster General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2020-10-05",
      "completion_date": "2022-08-11",
      "has_results": false,
      "last_update_posted_date": "2022-08-17",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 1,
      "location_summary": "Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530539"
    },
    {
      "nct_id": "NCT00614666",
      "title": "Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Coccidioidomycosis"
      ],
      "interventions": [
        {
          "name": "nikkomycin Z",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 6,
      "start_date": "2007-09",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2025-04-16",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00614666"
    },
    {
      "nct_id": "NCT07122986",
      "title": "A Study to Learn About a Vaccine Against E Coli in Healthy Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "E coli vaccine 1 Dose A",
          "type": "DRUG"
        },
        {
          "name": "E coli vaccine 1 Dose B",
          "type": "DRUG"
        },
        {
          "name": "E coli vaccine 2",
          "type": "DRUG"
        },
        {
          "name": "E coli vaccine 3",
          "type": "DRUG"
        },
        {
          "name": "E coli Vaccine 4 Dose A",
          "type": "DRUG"
        },
        {
          "name": "E coli Vaccine 4 Dose B",
          "type": "DRUG"
        },
        {
          "name": "E coli Vaccine 4 Dose C",
          "type": "DRUG"
        },
        {
          "name": "E coli Vaccine 5 Dose A",
          "type": "DRUG"
        },
        {
          "name": "E coli Vaccine 5 Dose B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-08-11",
      "completion_date": "2028-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 11,
      "location_summary": "Anaheim, California • Lake Forest, California • Walnut Creek, California + 6 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07122986"
    },
    {
      "nct_id": "NCT00703573",
      "title": "A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "S-777469 400 mg",
          "type": "DRUG"
        },
        {
          "name": "S-777469 800 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 209,
      "start_date": "2008-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-08",
      "last_synced_at": "2026-11-01T06:28:47.785Z",
      "location_count": 33,
      "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703573"
    }
  ]
}